Skip to Main Content

Advertisement

Umbrella Alt Text
header search
Search
Advanced Search
Skip Nav Destination

Immuno-oncology

Studies that investigate the immune system, its interactions with tumor cells, and opportunities to enhance the body's natural defenses against cancer

SUBMIT TO JOURNAL
Latest in Immuno-oncology
June 28 2022
A TCR-like CAR promotes sensitive antigen recognition and controlled T cell expansion upon mRNA vaccination
Matthias Birtel, Ralf-Holger Voss et al.
Chimeric antigen receptor (CAR) T cells are efficacious in patients with B cell malignancies, while their activity is limited in patients with solid tumors. We developed a novel heterodimeric TCR-like CAR (TCAR) designed to achieve optimal chain pairing and integration into the T cell CD3 signaling complex. The TCAR ...
June 28 2022
Depletion of Mannose Receptor–Positive Tumor-associated Macrophages via a Peptide-targeted Star-shaped Polyglutamate Inhibits Breast Cancer Progression in Mice
Anni Lepland, Alessio Malfanti et al.
Although many studies have explored the depletion of tumor-associated macrophages (TAM) as a therapeutic strategy for solid tumors, currently available compounds suffer from poor efficacy and dose-limiting side effects. Here, we developed a novel TAM-depleting agent (“OximUNO”) that specifically targets CD206+ TAMs and ...
June 27 2022
Interrogation of T Cell-Enriched Tumors Reveals Prognostic and Immunotherapeutic Implications of Polyamine Metabolism
Richard A Harbison, Rajeev Kumar Pandey et al.
Metabolic features of the tumor microenvironment (TME) antagonize anti-tumor immunity. We hypothesized that T cell infiltrated tumors with a known antigen should exhibit superior clinical outcomes, though some fare worse given unfavorable metabolic features leveraging T cell-infiltrated (Thi), human papillomavirus-related ...
June 24 2022
Avian paramyxovirus 4 (APMV-4) antitumor activity leads to complete remissions and long-term protective memory in preclinical melanoma and colon carcinoma models
Aryana Javaheri, Yonina Bykov et al.
Avulaviruses represent a diverse subfamily of non-segmented negative strand RNA viruses infecting avian species worldwide. To date, 22 different serotypes have been identified in a variety of avian hosts, including wild and domestic birds. APMV-1, also known as Newcastle disease virus (NDV), is the only avulavirus that ...
June 16 2022
Impaired anti-tumor immune response in MYCN-amplified neuroblastoma is associated with lack of CCL2 secretion and poor dendritic cell recruitment
Jamila Kacher, Olivier Manches et al.
In neuroblastoma (NB), MYCN amplification is associated with sparse immune infiltrate, and poor prognosis. Dendritic cells (DCs) are crucial immune sentinels but their involvement in NB pathogenesis is poorly understood. We observed that the migration of monocytes, MDC and PDC induced by MYCN non-amplified NB supernatants ...
June 09 2022
The Tumor Immune Profile of Murine Ovarian Cancer Models: An Essential Tool for Ovarian Cancer Immunotherapy Research
Galaxia M. Rodriguez, Kristianne J.C. Galpin et al.
Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer with an imperative need for new treatments. Immunotherapy has had marked success in some cancer types; however, clinical trials studying the efficacy of immune checkpoint inhibitors for the treatment of EOC benefited less than 15% of patients. Given ...
May 09 2022
Neoantigen Presentation and IFNγ Signaling on the Same Tumor-associated Macrophage are Necessary for CD4 T Cell–mediated Antitumor Activity in Mice
Ainhoa Perez-Diez, Xiangdong Liu et al.
Tumor-associated macrophages (TAM) promote tumor survival, angiogenesis, and metastases. Although they express MHC class II molecules, little is known about their ability to present tumor antigens to tumor-infiltrating CD4 T cells, and the consequences of such presentation. To answer these questions, we used a C57/BL10 ...
May 09 2022
Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas
Anne W.J. Martens, Joanne M. Rietveld et al.
T-cell redirecting bispecific antibodies hold high promise for treatment of B-cell malignancies. B-cell maturation antigen (BCMA) exhibits high expression on normal and malignant mature B cells including plasma cells, which can be enhanced by inhibition of γ-secretase. BCMA is considered a validated target in multiple ...
May 05 2022
Safety and Efficacy of Engineered Toxin Body MT-3724 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphomas and Diffuse Large B-cell Lymphoma
Paul A. Hamlin, Vasile Musteata et al.
MT-3724, a novel engineered toxin body comprised of an anti-CD20 single-chain variable fragment genetically fused to Shiga-like Toxin A subunit, is capable of binding to and internalizing against CD20, inducing cell killing via permanent ribosomal inactivation. This study evaluated MT-3724 in patients with ...
March 23 2022
Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors
Ana M. Metelo, Agnieszka Jozwik et al.
Multiple myeloma remains an incurable plasma cell malignancy despite the rapidly evolving treatment landscape. Chimeric antigen receptor T cells targeted against BCMA have recently shown great promise in relapsed refractory multiple myeloma; however, all patients ultimately still progress from their disease. Lack of CAR ...
View all Immuno-oncology articles

Topics in Immuno-oncology

AACR Journals

 

 

  • Copyright © 2022 by the American Association for Cancer Research.
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept